Answers are grounded in this paper and cite their sources.
The prevalence of manifesting XL-MTM carriers may be higher than currently assumed, most having a mild phenotype and a wide variety of symptoms. Manifesting carriers are particularly affected by fatigue, limitations of daily activities, pain, and reduced quality of life. Our findings should increase awareness and provide useful information for health care providers and future clinical trials.
No takes yet. Share an insight, caveat, or question.
Reumers et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: